Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns

# Drug Oversight Urged for Nutraceuticals

By Aditi Rao, Senior Health Policy Reporter, April 19, 2026

In a decisive move to safeguard public health, prominent healthcare non-governmental organizations (NGOs) and consumer advocacy groups have petitioned the Indian government to shift the regulatory oversight of nutraceuticals from food authorities to the national drug regulator. Prompted by escalating concerns over substandard product quality, misleading health claims, and exorbitant pricing, advocates argue that dietary supplements and vitamins are currently exploiting a dangerous regulatory grey area. With the domestic nutraceutical market ballooning to record valuations by early 2026, stakeholders stress that enforcing pharmaceutical-grade scrutiny is now imperative to protect consumers from unregulated, potentially hazardous products masquerade as therapeutic cures. [Source: Hindustan Times | Additional: National Health Data 2026].

## The Expanding Regulatory Grey Area

For years, the lines between traditional pharmaceuticals and nutraceuticals—encompassing dietary supplements, functional foods, vitamins, and herbal extracts—have grown increasingly blurred. Currently, nutraceuticals in India are governed under the Food Safety and Standards Act of 2006, falling primarily under the purview of the Food Safety and Standards Authority of India (FSSAI). Because these products are legally classified as “food” rather than “drugs,” they bypass the rigorous clinical trials, efficacy testing, and strict quality control measures mandated by the Central Drugs Standard Control Organisation (CDSCO).

This bifurcation in regulation has created a lucrative loophole for manufacturers. A product containing a specific dosage of Vitamin D or Zinc, for instance, can be registered as a dietary supplement under the FSSAI with relative ease, avoiding the years of scrutiny required to register the exact same molecule as a therapeutic drug under the CDSCO. Health activists note that while the FSSAI is well-equipped to monitor standard food safety, its infrastructure is not designed to evaluate the complex pharmacological interactions, bioavailability, and therapeutic claims of concentrated chemical compounds and potent botanical extracts.

## Quality Red Flags and Public Health Risks

The push for tighter oversight has been catalyzed by a comprehensive report published by a coalition of public health NGOs, which flagged alarming rates of adulteration and contamination within the nutraceutical supply chain. As the post-pandemic wellness boom stabilized into a permanent consumer habit by 2026, the market was flooded with thousands of new supplement brands, many operating primarily through unregulated e-commerce channels.

**Key quality concerns highlighted in the recent NGO petitions include:**
* **Active Pharmaceutical Ingredient (API) Lacing:** Routine testing has uncovered dietary supplements illegally spiked with scheduled prescription drugs. For example, some over-the-counter herbal weight-loss supplements were found to contain Sibutramine (a banned appetite suppressant), while certain sports nutrition and muscle-building powders were laced with anabolic steroids to artificially boost results.
* **Heavy Metal Contamination:** A significant portion of botanical and herbal nutraceuticals sourced from unverified suppliers tested positive for dangerous levels of heavy metals, including lead, arsenic, and mercury, posing severe long-term risks of organ damage and neurological disorders.
* **Misleading Claims:** Despite FSSAI guidelines prohibiting supplements from claiming to cure or mitigate diseases, product packaging and digital marketing campaigns frequently utilize borderline terminology. Phrases like “supports cardiac healing,” “reverses metabolic syndrome,” or “manages diabetic neuropathy” trick consumers into substituting critical, evidence-based medications with unproven supplements.

Dr. Sameer Deshpande, a clinical pharmacologist and public health researcher, emphasizes the danger of this trend: “When a consumer ingests a pharmaceutical pill, they are guaranteed a specific milligram of the active ingredient with proven dissolution rates. With nutraceuticals under current food laws, batch-to-batch variations are massive. A patient relying on an unregulated botanical extract for cholesterol management is playing Russian roulette with their cardiovascular health.”

## The Pricing Paradox and Consumer Exploitation

Beyond clinical safety, the economic exploitation of patients has become a primary focal point for NGOs demanding CDSCO intervention. The pharmaceutical sector in India is subject to the Drugs (Prices Control) Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA). The NPPA strictly caps the profit margins on the National List of Essential Medicines (NLEM), ensuring life-saving drugs remain affordable to the masses.

Nutraceuticals, however, are exempt from these price controls. Because they are legally classified as food supplements, manufacturers can dictate maximum retail prices (MRP) based solely on market demand, marketing expenses, and perceived brand value. Consequently, pharmaceutical companies often launch the same vitamin or mineral complex under an FSSAI license rather than a CDSCO license, allowing them to legally bypass price caps and charge exorbitant premiums.

### Price Disparity Analysis: Drugs vs. Nutraceuticals

| Product Type | Regulatory Authority | Average MRP (Per 10 Tablets/Capsules) | Price Cap Imposed |
| :— | :— | :— | :— |
| Standard Vitamin C (500mg) | CDSCO (Drug) | ₹15 – ₹25 | Yes (NLEM Guidelines) |
| “Immunity Boosting” Vitamin C | FSSAI (Supplement) | ₹150 – ₹400 | No |
| Standard Folic Acid/Iron | CDSCO (Drug) | ₹20 – ₹35 | Yes |
| Premium “Women’s Wellness” Iron | FSSAI (Supplement) | ₹300 – ₹600 | No |
| Basic Omega-3 / Fish Oil | CDSCO (Drug) | ₹60 – ₹90 | Yes |
| “Advanced Joint Support” Omega-3 | FSSAI (Supplement) | ₹800 – ₹1,500 | No |

*Data representation based on 2026 market averages. [Source: Health Policy Consumer Watchdog Data]*

NGO advocates point out a disturbing trend in the medical ecosystem: pharmaceutical sales representatives frequently incentivize physicians to prescribe the costlier “nutraceutical” variants of common vitamins rather than the cheaper, price-capped drug equivalents. This artificially inflates out-of-pocket healthcare expenditures for middle- and lower-income households who trust their physicians’ prescriptions implicitly.

## Industry Pushback and Economic Implications

The proposal to mandate drug-regulator oversight for nutraceuticals has not been met without resistance. The Indian nutraceutical industry, valued at roughly $12 billion in 2024 and projected to surpass $20 billion by 2027, is a significant driver of domestic manufacturing and exports. Industry lobbying groups, representing both massive multinational corporations and thousands of Micro, Small, and Medium Enterprises (MSMEs), argue that draconian regulations will stifle innovation and decimate smaller players.

Representatives from the nutraceutical manufacturing sector argue that classifying supplements as drugs is a fundamental misunderstanding of the product category. “Nutraceuticals are meant for preventive healthcare, nutrition supplementation, and wellness optimization, not acute disease treatment,” stated a spokesperson for a leading dietary supplement consortium. “Subjecting a basic multivitamin or a whey protein isolate to the same multi-phase clinical trial requirements as an oncology drug will increase production costs by hundreds of percentages. That cost will ultimately be passed down to the consumer, making basic preventive nutrition entirely unaffordable.”

Furthermore, industry leaders suggest that rather than a complete handover to the CDSCO, the government should focus on strengthening the FSSAI’s enforcement capabilities. They advocate for a specialized sub-division within the food safety authority, equipped with dedicated laboratories and stricter penal codes for bad actors who adulterate products or make false claims, rather than punishing the compliant majority of the industry.

## Global Best Practices and the Road Ahead

As Indian policymakers weigh the demands of public health NGOs against the economic concerns of the industry, they are increasingly looking toward global regulatory frameworks for guidance.

In the United States, dietary supplements are regulated by the FDA under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which still treats them more like food than drugs, often leading to similar controversies regarding post-market enforcement. Conversely, Australia’s Therapeutic Goods Administration (TGA) utilizes a highly regarded two-tiered system. The TGA classifies many nutraceuticals as “Complementary Medicines,” requiring them to be manufactured in facilities adhering to strict pharmaceutical Good Manufacturing Practices (GMP) and mandating pre-market evidence for any health claims made on the label.

Health policy experts in India are currently drafting recommendations for a hybrid model—one that creates a distinct, third regulatory category specifically for nutraceuticals. This proposed “Health Supplements and Functional Foods” division would be jointly monitored by scientific committees from both the FSSAI and the CDSCO. Under this proposed framework, products making specific structural or functional claims would require clinical validation similar to over-the-counter (OTC) medicines, while simple nutritional gap-fillers would remain under enhanced food-safety protocols.

## Conclusion: Balancing Wellness with Accountability

The petition to transfer nutraceutical oversight to the drug regulator marks a critical juncture in India’s public health policy. The convergence of rising health consciousness and aggressive corporate marketing has transformed dietary supplements into essential commodities for millions of households. However, the recurring lapses in product quality, combined with unchecked pricing strategies that exploit regulatory blind spots, underscore an urgent need for systemic reform.

As the Ministry of Health and Family Welfare reviews the NGO submissions this quarter, consumers must remain vigilant. Until a unified, rigorous regulatory framework is established, public health experts advise consulting with registered medical practitioners before beginning any supplement regimen, prioritizing products with third-party independent lab testing, and remaining skeptical of nutraceuticals making miraculous therapeutic claims. The ultimate goal for 2026 and beyond must be an ecosystem where preventive wellness is accessible, affordable, and above all, unequivocally safe.